Needham & Company Upgrades Achaogen (AKAO) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Achaogen Announces Positive Results in Phase 3 cUTI and CRE Clinical Trials of Plazomicin
December 12, 2016 7:00 AM EST-- EPIC registration trial successfully achieves FDA primary endpoints in patients with complicated urinary tract infections (cUTI) --
-- EPIC demonstrates superiority on EMA primary endpoints --
-- CARE descriptive trial shows 71 percent relative reduction in Day 28 all-cause mortality compared with colistin in patients with serious CRE infections --
-- Plazomicin well tolerated in both trials and shows improved overall safety compared with colistin in CARE trial --
-- Company plans to... More
